APC-resistenz bei faktor-V-Leiden: Wie hoch ist das thromboserisiko?

Deutsche Medizinische Wochenschrift

Volumn 123, Issue 6, 1998, Pages 137-139

  Spannagl, M ^a   Schramm, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT; PROTEIN C;

BLOOD CLOTTING DISORDER; ESTROGEN THERAPY; GENETICS; HETEROZYGOTE; HUMAN; METABOLISM; POINT MUTATION; REVIEW; RISK FACTOR; THROMBOSIS;

BLOOD COAGULATION DISORDERS; CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; FACTOR V; HETEROZYGOTE; HUMANS; POINT MUTATION; PROTEIN C; RISK FACTORS; THROMBOSIS;

EID: 0032488689     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023917     Document Type: Article

References (11)

1. Bertina, R. M., B. P. C. Koeleman.T. Koster, F. R. Rosendaal, R.J. Dinven, H. de Ronde, P. A. van der Velden, P. H. Reitsma: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994), 64-67.
2. Dahlbäck, B., M. Carlson, P. J. Sevennson: Familial thrombophilia due to a previously unrecognized mechanism characterised by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 90 (1993), 1004-1008. -
3. Desmarais, S., P. de Moerloose, G. Reber, P. Minazio, A. Perrier, H. Bounameaux: Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 347 (1996), 1374-1375.
4. Dick, A. M. SpannagI: Faktor-V-Leiden-Mutation mit Resistenz gegen aktives Protein C. Phlebol. 26 (1997), l -9.
5. Eichinger, S., J. Pabinger, A. Stumpflen, M. Hirschl, C. Bialonczyk, B. Schneider. C. Mannhalter. E. Minar, K. Lechner, P. A. Kyrie: The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thrombos. Haemost. 77 (1997), 624 - 628.
6. Emmerich, J., M. Alhenc-Gelas. M. F. Aillaud. I. Juhan-Vague, B. Jude, J. M. Garcin, M. Dreyfus, P. de Moerloose, A. Le Querrec, P. Prioleet, M. Berruyer, X. Vallatin. M. Wolf, M. Arach, J. N. Fiessinger: Clinical Features in 36 patients homozygous for the ARG 506 - GLN Factor V-Mutation. Thrombosis and Haemostasis 77 (1997). 620-623.
7. Grandone, E., M. Margaglione, D. Colaizzo, M. d'Äddedda, G. Cappucci, G. Veccione, N. Scianname, G. Pavone, G. Di Minno: Factor V-Leiden is associated with repeated and recurrent unexplained fetal losses. Thrombose and Haemostasis 77 (1977), 822-824.
8. Ridker, P. M., C. H. Hennekens, K. Lindpaintner, M.J. Stampfer, P. R. Eisenberg, J. P. Miletich: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. New Engl.J. Med. 332 (1995), 912-917.
9. Schramm. W., M. SpannagI, T. Szucs, L Heinemann: Bavarian Study on Clinical Relevance of thromboembolic risk factors in women taking oral contraceptives. Ann. Haematol. 74 Suppl. A/98 (1997).
10. Simioni, P., P. Prandoni, W. A. Lensing, A. Scudeller, C. Dardells, M. H. Prins, S. Villalta. F. Dazzi, A. Rirolami: The risk of recurrent venous thromboembolism in patients with an ARG 506-Gln mutation in the gene for Factor V. New Engl.J. Med. (1997), 336: 339-403.
11. Vandenbroucke,J. P., T. Koster, E. Briet, R. H. Reitsma, R. M. Bertina, F. R. Rosendaal: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 346(1994), 1575-1582.